Parkin disease: a phenotypic study of a large case series

Brain. 2003 Jun;126(Pt 6):1279-92. doi: 10.1093/brain/awg142.

Abstract

Mutations in the parkin gene, PARK2, are a common cause of parkinsonism in familial as well as isolated cases with an age of onset <40 years and should be considered in the diagnostic work up of young-onset parkinsonism. We report a detailed clinical evaluation of a personal series of 24 patients with mutations in the parkin gene. The clinical presentation of most cases was broadly comparable to that of previous descriptions of autosomal recessive early-onset or juvenile parkinsonism and young-onset Parkinson's disease and also had similarities with phenotypes of dopa-responsive dystonia. However, our only case with consanguineous parents had an age of onset of 54 years. We report three new phenotypes at presentation: cervical dystonia; autonomic dysfunction and peripheral neuropathy; and pure exercise-induced dystonia. We emphasize a number of clinical features that can be seen in parkin disease: focal dystonia; early instability; freezing; festination or retropulsion; concurrent autonomic failure; dramatic response to anticholinergics; early or atypical L-dopa-induced dyskinesias; exquisite sensitivity to small doses of L-dopa; and recurrent psychosis, even taking L-dopa alone. We also report behavioural disorder prior to the onset of parkinsonism. Some relatives carrying a single parkin mutation without extrapyramidal symptoms or signs also had psychiatric symptoms that might be related to their carrier status.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age of Onset
  • Aged
  • Aged, 80 and over
  • Autonomic Nervous System Diseases / genetics
  • Dystonia / genetics
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Levodopa / therapeutic use
  • Ligases / genetics*
  • Male
  • Mental Disorders / etiology
  • Mental Disorders / genetics
  • Middle Aged
  • Mutation*
  • Parkinsonian Disorders / drug therapy
  • Parkinsonian Disorders / genetics*
  • Parkinsonian Disorders / psychology
  • Pedigree
  • Phenotype
  • Polymerase Chain Reaction / methods
  • Ubiquitin-Protein Ligases*

Substances

  • Levodopa
  • Ubiquitin-Protein Ligases
  • parkin protein
  • Ligases